Skip to content

Study · Animal study (in vivo) · mouse · 2015

10 results

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C

Neuroscience2 Jul 2015Cited by 209 (Europe PMC)

PMID26141845 (opens in a new tab)DOI10.1016/j.neuroscience.2015.06.054 (opens in a new tab)PepBankPUB-26141845
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, liraglutide prevented motor impairment assessed with Rotarod, open-field locomotion, and catalepsy testing.

    In plain wordsIn mice exposed to MPTP, liraglutide prevented impaired movement.

    Peptide
    Liraglutide
    Outcome
    DecreaseMPTP-induced motor impairment
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test),
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, lixisenatide prevented motor impairment assessed with Rotarod, open-field locomotion, and catalepsy testing.

    In plain wordsIn mice exposed to MPTP, lixisenatide prevented impaired movement.

    Peptide
    Lixisenatide
    Outcome
    DecreaseMPTP-induced motor impairment
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test),
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, liraglutide prevented reduced tyrosine hydroxylase levels in the substantia nigra and basal ganglia.

    In plain wordsIn mice exposed to MPTP, liraglutide prevented loss of tyrosine hydroxylase in two brain regions.

    Peptide
    Liraglutide
    Outcome
    IncreaseTyrosine hydroxylase levels
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test), reduction in tyrosine hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia,
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, lixisenatide prevented reduced tyrosine hydroxylase levels in the substantia nigra and basal ganglia.

    In plain wordsIn mice exposed to MPTP, lixisenatide prevented loss of tyrosine hydroxylase in two brain regions.

    Peptide
    Lixisenatide
    Outcome
    IncreaseTyrosine hydroxylase levels
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test), reduction in tyrosine hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia,
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In MPTP-treated mice, liraglutide reduced the pro-apoptotic signaling molecule BAX.

    In plain wordsIn mice exposed to MPTP, liraglutide reduced BAX, a cell-death signaling molecule.

    Peptide
    Liraglutide
    Outcome
    DecreaseBAX
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2.
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In MPTP-treated mice, lixisenatide reduced the pro-apoptotic signaling molecule BAX.

    In plain wordsIn mice exposed to MPTP, lixisenatide reduced BAX, a cell-death signaling molecule.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBAX
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2.
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In MPTP-treated mice, liraglutide increased the anti-apoptotic signaling molecule B-cell lymphoma-2.

    In plain wordsIn mice exposed to MPTP, liraglutide increased B-cell lymphoma-2, a cell-survival signaling molecule.

    Peptide
    Liraglutide
    Outcome
    IncreaseB-cell lymphoma-2
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2.
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In MPTP-treated mice, lixisenatide increased the anti-apoptotic signaling molecule B-cell lymphoma-2.

    In plain wordsIn mice exposed to MPTP, lixisenatide increased B-cell lymphoma-2, a cell-survival signaling molecule.

    Peptide
    Lixisenatide
    Outcome
    IncreaseB-cell lymphoma-2
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2.
    3 context sentences
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, liraglutide showed greater neuroprotection than exendin-4 at the tested doses.

    In plain wordsIn MPTP-treated mice, liraglutide protected nerves more than exendin-4 at the tested doses.

    Peptide
    Liraglutide
    Outcome
    IncreaseNeuroprotection versus exendin-4
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Comparator
    Exendin-4, 10 nmol/kg
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    The results demonstrate that in this study, both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
    3 context sentences
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In MPTP-treated mice, lixisenatide showed greater neuroprotection than exendin-4 at the tested doses.

    In plain wordsIn MPTP-treated mice, lixisenatide protected nerves more than exendin-4 at the tested doses.

    Peptide
    Lixisenatide
    Outcome
    IncreaseNeuroprotection versus exendin-4
    Study

    mousen: not reported in source

    MPTP mouse model of Parkinson's disease
    Comparator
    Exendin-4, 10 nmol/kg
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg once daily · intraperitoneal · 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    The results demonstrate that in this study, both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
    3 context sentences
    Summary · context
    When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen.
    Summary · context
    MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.
    Summary · context
    Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.